G. Published 60-Day FRN

22688

Federal Register / Vol. 83, No. 95 / Wednesday, May 16, 2018 / Notices

valid assumptions and methodology;
ways to enhance the quality, utility, and
clarity of the information to be
collected; and ways in which we can
minimize the burden of the collection of
information on those who are to
respond, through the use of appropriate
technological collection techniques or
other forms of information technology.
OBTAINING COPIES OF PROPOSALS:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW, Washington, DC
20405, telephone 202–501–4755. Please
cite OMB Control No. 9000–0035,
Claims and Appeals, in all
correspondence.
Dated: May 10, 2018.
Lorin Curit,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2018–10408 Filed 5–15–18; 8:45 am]
BILLING CODE 6820–EP–P

GENERAL SERVICES
ADMINISTRATION

DATES:

The rescission is as of May 16,

2018.
For
clarification of content, please contact
Mr. Cy Greenidge, Office of
Government-wide Policy, Office of
Asset and Transportation Management,
at 202–219–2349, or by email at
travelpolicy@gsa.gov. Please cite Notice
of FTR Bulletin 18–04.
SUPPLEMENTARY INFORMATION: Executive
Order 13777, Enforcing the Regulatory
Reform Agenda, Section 3, paragraph
(d)(ii), states in part, the Regulatory
Reform Task Force shall attempt to
identify regulations that are outdated,
unnecessary, or ineffective. GSA has
conducted a thorough review of all FTR
bulletins on the FTR Travel/Per Diem
Bulletins website (https://www.gsa.gov/
policy-regulations/regulations/federaltravel-regulation/federal-travelregulation-and-related-files#Travel
PerDiemBulletins) and determined that
some of the Bulletins contain outdated,
duplicative, expired, or inapplicable
content. FTR Bulletin 18–04 lists all
rescinded bulletins meeting one of the
aforementioned criterion.
FOR FURTHER INFORMATION CONTACT:

Dated: May 11, 2018.
Alexander Kurien,
Deputy Associate Administrator, Office of
Asset and Transportation Management,
Office of Government-wide Policy.

[Notice–MA–2018–03; Docket No. 2018–
0002, Sequence No. 7]

Rescission of FTR Bulletins

[FR Doc. 2018–10436 Filed 5–15–18; 8:45 am]

Office of Government-wide
Policy (OGP), General Services
Administration (GSA).
ACTION: Notice of Federal Travel
Regulation (FTR) Bulletin 18–04,
rescission of FTR Bulletins.

BILLING CODE 6820–14–P

AGENCY:

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

GSA is officially rescinding
various FTR bulletins to ensure the
Travel/Per Diem Bulletin section on the
agency’s FTR website displays only
current information. Agencies’ policies
should be updated as warranted.

SUMMARY:

OMB No.: 0970–0383.
Description: The Family and Youth
Services Bureau (FYSB) and the Office
of Planning, Research, Evaluation
(OPRE) in the Administration for
Children and Families (ACF) are
requesting to continue collecting data as
part of a currently approved information
collection (OMB No. 0970–0383). The
purpose is to continue baseline data
collection at study enrollment and
follow-up data collection for the
Evaluation of the Transitional Living
Program (TLP). The TLP evaluation was
designed to examine the effects of
FYSB’s Transitional Living Program on
runaway and homeless youth, focusing
on such outcomes as housing and
homelessness, education or training,
employment, social connections, socioemotional well-being, and risk
behaviors.
Data collection will include three
primary surveys, previously approved
by OMB: (1) A survey administered at
the time of TLP enrollment (baseline),
(2) a survey administered 6 months after
enrollment, which will collect
information on short-terms outcomes;
and (3) a survey administered at 12
months, which will collect information
on longer-term outcomes. Participants
will be enrolled through the TLP study
sites.
Respondents: Runaway and homeless
youth ages 16 to 22 who agree to
participate in the study upon
enrollment into one of the TLP study
sites.

Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Title: Evaluation of the Transitional
Living Program (TLP).

ANNUAL BURDEN ESTIMATES
Total
number of
respondents

Instrument

sradovich on DSK3GMQ082PROD with NOTICES

Young Adult Baseline Survey ..............................................
Young Adult 6-Month Follow Up Survey .............................
Young Adult 12-Month Follow Up Survey ...........................

Estimated Total Burden Hours: 368.
In compliance with the requirements
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the

VerDate Sep<11>2014

17:34 May 15, 2018

Jkt 244001

Annual
number of
respondents

600
600
600

200
200
200

information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research,
and Evaluation, 330 C Street SW,

PO 00000

Frm 00078

Fmt 4703

Sfmt 4703

Number of
responses per
respondent
1
1
1

Average
burden hours
per
response
0.62
0.61
0.61

Annual burden
hours
124
122
122

Washington, DC 20201, Attn: OPRE
Reports Clearance Officer. Email
address: OPREinfocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.

E:\FR\FM\16MYN1.SGM

16MYN1

Federal Register / Vol. 83, No. 95 / Wednesday, May 16, 2018 / Notices
The Department specifically requests
comments on (a) whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2018–10461 Filed 5–15–18; 8:45 am]
BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–1773]

Blood Products Advisory Committee;
Notice of Meeting
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice.

The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Blood Products Advisory
Committee. The general function of the
Blood Products Advisory Committee is
to provide advice and recommendations
to the Agency on regulatory issues
related to blood and products derived
from blood. On the first day of the
meeting, the Committee will provide
advice regarding bacterial risk control
strategies to enhance the safety and
availability of platelets for transfusion.
On the second day of the meeting, the
Committee, supplemented with
members from the Microbiology Devices
Panel of the Medical Devices Advisory
Committee, will function as a medical
device panel to provide advice and
recommendations to the Agency on
classification of devices. The meeting
will be open to the public.
DATES: The meeting will be held on July
18, 2018, from 8 a.m. to 5 p.m. and July
19, 2018, from 8 a.m. to 3 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503, sections B and C), Silver Spring,

sradovich on DSK3GMQ082PROD with NOTICES

SUMMARY:

VerDate Sep<11>2014

17:34 May 15, 2018

Jkt 244001

MD 20993–0002. Answers to commonly
asked questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Bryan Emery, Division of Scientific
Advisors and Consultants, Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71,
Rm. 6268, Silver Spring, MD 20993–
0002, 240–402–8054, bryan.emery@
fda.hhs.gov; or Joanne Lipkind, Division
of Scientific Advisors and Consultants,
CBER, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71,
Rm. 6270, Silver Spring, MD 20993–
0002, 240–402–8106, joanne.lipkind@
fda.hhs.gov; or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting. For those unable to attend in
person, the meeting will be also be
available via webcast. The webcast will
be available at the following link on
both days: https://collaboration.fda.gov/
bpac0718/.
SUPPLEMENTARY INFORMATION:
Agenda: On July 18, 2018, the Blood
Products Advisory Committee will meet
in open session to discuss and provide
advice regarding bacterial risk control
strategies for blood collection
establishments and transfusion services
to enhance the safety and availability of
platelets for transfusion. The Committee
will discuss the available strategies to
control the risk of bacterial
contamination of platelets with 5-day
and 7-day dating, including bacterial
testing using culture-based devices and
rapid bacterial detection devices and
implementation of pathogen reduction
technology.
On July 19, 2018, the Committee will
function as a medical device panel. The
Committee will meet in open session to
discuss and provide advice regarding
the device reclassification from class III
to class II of nucleic acid and serology-

PO 00000

Frm 00079

Fmt 4703

Sfmt 4703

22689

based point-of-care and laboratory-based
in vitro diagnostic devices indicated for
use as aids in the diagnosis of human
immunodeficiency virus (HIV)
infection. The devices that will be
discussed by the Committee during the
meeting are post-amendment devices
that currently are classified into class III
under section 513(f)(1) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
360c(f)(1)).
FDA intends to make background
material available to the public
approximately 2 weeks and no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s website after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 11, 2018. Oral
presentations from the public will be
scheduled between approximately 2:15
p.m. and 3:15 p.m. on July 18, 2018, and
between 12:30 p.m. and 1:30 p.m. on
July 19, 2018. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before July 5,
2018. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 6, 2018.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Bryan Emery

E:\FR\FM\16MYN1.SGM

16MYN1